Colorado Center for Nanomedicine and Nanosafety

The Colorado Center for Nanomedicine and Nanosafety will promote collaborative effort, stimulate learning, and advance multidisciplinary research and education in the areas of basic and applied nanomedicine and nanosafety, between academic labs and the local and national biotech and pharma companies.

  • The CCNN was established within the Skaggs School of Pharmacy and Pharmaceutical Sciences in 2016.
  • The CCNN will include members from University of Colorado Anschutz Medical Campus, other University of Colorado campuses and any other interested, qualifying professionals from the State of Colorado.
  • The CCNN will lead the discovery of new diagnostics and therapeutic approaches that could be translated and commercialized.
  • The CCNN will provide intellectual, technical and financial resources in the research and service areas of nanotechnology and nanomedicine to collaborators from a diverse range of disciplines.
  • The CCNN will promote the penetration of nanomedicine and nanosafety into clinical and translational research in order to foster future development of treatments and diagnostics and improve the safety and use of nanomedicines.
  • The CCNN will increase the awareness of safety and toxicity issues associated with nanomaterials and the role of environmental nanomaterials in the pathology of disease.
  • The CCNN will enhance the national and international visibility of the current efforts at the University of Colorado in the field of nanomedicine and nanosafety.
  • The CCNN will provide training and education of clinical and basic scientists.

Sponsors: Skaggs School of Pharmacy and Pharmaceutical Sciences, ALSAM foundation​​

Synthesis and evaluation of magnetic nanoparticles, MRI contrast agents, near infrared probes, ultrasound microbubbles, liposomes, PLGA nanoparticles

Toxicity and safety assessment of nanomaterials including cell viability, cellular uptake/dosimetry, cellular and tissue imaging, hyperspectral imaging, biodistribution, inflammatory responses.

Small molecule, peptide, protein, and nucleic acid loaded nanoparticles for enhanced drug/gene delivery; ligand functionalized nanoparticles for targeted delivery; pure drug nanoparticles and nanotubes; polymeric, protein, and viral capsid nanoparticles. ​​

​Equipment available to members of the CCNN:

  • Fiber optic based near infrared spectroscopy system (FONIRS) 2 NIR wavelengths
  • CytoViva Enhanced Darkfield Hyperspectral Microscope
  • Malvern Zetasizer
  • Perkin Elmer ICP-MS with HPLC and single cell/nanoparticle capability
  • Guava flow cytometer with high throughput capability

List to be expanded.​

Past Events

2nd Symposium on Nanomedicine and Nanosafety

March 24th, 2017


3rd Symposium on Nanomedicine and Nanosafety

April 26th, 2018


4th Symposium on Nanomedicine a​nd Nanosafety

April 26th, 2019


5th Symposium on Nanomedicine a​nd Nanosafety

April 30th, 2020 - cancelled due to COVID-19.

Jared Brown

Jared Brown PhD

Professor Toxicology Graduate Program Director, T32 Training Program in Molecular and Systems Toxicology Director, Colorado Center for Nanomedicine and Nanosafety Co-Director
  • Department of Pharmaceutical Sciences


Primary Phone:303-724-8213

Mailing Address:
  • CU Anschutz

Pharmacy and Pharmaceutical Sciences Building

12850 East Montview Boulevard

Third Floor Room 3129

Aurora, CO 80045

Research in the Brown lab is focused on immune responses to particles including nanoparticles, air pollution, silica and coal dust. In particular, our research group investigates the role of innate immune cells, including mast cells and macrophages, in response to particles. In addition, we are interested in understanding the toxicity of engineered nanomaterials as well as their use in drug delivery and treatment of cancer.

Education, Licensure & Certifications

  • BS, Colorado State University, Fort Collins, CO
  • PhD, University of Montana, Center for Environmental Health Sciences, Skaggs School of Pharmacy, Missoula, MT
  • Postdoctoral – Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD

CMS Login